SQLite Web: event_store.db

Update row 473711 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:6805896f18e19993","evidence_event_ids":["evt_b461989bb314"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-ataibeckley-stock-surged-today","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.fool.com/investing/2026/04/20/why-ataibeckley-stock-surged-today/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-ataibeckley-stock-surged-today","article_chars":3052,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_a27267c8752577fe","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/20/why-ataibeckley-stock-surged-today/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T22:07:42.588220+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsPromising therapies for mental illnesses could see their regulatory reviews quickened.","fetched_title":"Why AtaiBeckley Stock Surged Today | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-ataibeckley-stock-surged-today","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-ataibeckley-stock-surged-today","source_event_id":"evt_b461989bb314","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"05f8a62fc32c4785","kind":"unusual_volume","published_at":"2026-04-21T02:11:41+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["Monday"],"entities":[{"asset_class":"equity","name":"AtaiBeckley","relevance":"high","symbol":"ATAI","type":"company"},{"asset_class":"other","name":"President Donald Trump","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"U.S. health regulators","relevance":"medium","symbol":"","type":"government_body"},{"asset_class":"other","name":"U.S. Food and Drug Administration (FDA)","relevance":"medium","symbol":"","type":"government_body"}],"event_type":"regulation","information_gaps":["Unusual volume details are missing: baseline volume, volume ratio vs average, and direction (e.g., above/below average) are not provided in the text.","The signal type is discovery_unusual_volume_delta, but the article content provided does not include any volume metrics or confirmation of unusual volume beyond the price move.","No explicit confirmation is provided that the volume surge (if any) was caused by the executive order; the article only links the stock price jump to the regulatory directive.","No specific date of the executive order or the trading session date is provided beyond 'Monday'.","No quantitative details are provided for the expected review timeline beyond 'as few as one to two months' for breakthrough-therapy designations."],"key_facts":["Shares of AtaiBeckley (NASDAQ: ATAI) leaped on Monday.","By the close of trading, AtaiBeckley\u2019s stock price was up more than 21%.","The article attributes the move to President Donald Trump directing U.S. health regulators to accelerate reviews of psychedelic treatments for severe mental illnesses.","The executive order aims to reduce regulatory evaluation timelines for certain psychedelic compounds.","The article states that drugs with FDA breakthrough-therapy designations could see reviews completed in as few as one to two months.","The article says AtaiBeckley is developing a nasal spray for treatment-resistant depression.","The investigational drug BPL-003 is described as having breakthrough therapy designation and Phase 2 results.","The article states AtaiBeckley expects to begin Phase 3 trials later this year."],"numeric_claims":[{"label":"intraday_close_gain_percent","value":"more than 21%"}],"primary_claim":"AtaiBeckley\u2019s shares rose more than 21% by the close of trading following Trump\u2019s executive order to speed up regulatory reviews for psychedelic treatments.","relevance_score":0.78,"sentiment":"positive","source_quality":"high","summary":"AtaiBeckley (NASDAQ: ATAI) surged on Monday after President Donald Trump directed U.S. health regulators to accelerate FDA reviews of certain psychedelic treatments for severe mental illnesses.","topics":["psychedelic treatments","FDA regulatory review acceleration","executive order","severe mental illnesses","breakthrough-therapy designation","AtaiBeckley BPL-003","Phase 2/Phase 3 trials"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsPromising therapies for mental illnesses could see their regulatory reviews quickened.","tickers":[],"title":"Why AtaiBeckley Stock Surged Today","url":"https://www.fool.com/investing/2026/04/20/why-ataibeckley-stock-surged-today/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel